fmihealthcare-blog

[fmihealthcare-blog]

Dialysis Equipment Market is expected to expand at 4.8% CAGR in 2028

                          Patients with end-stage renal disease (ESRD) currently have two treatment options – kidney transplant and dialysis. The limited number of kidney donors worldwide and the various medical complications that arise from dialysis have pushed the medical fraternity to look for suitable alternatives to treat ESRD. Implantable bio artificial kidneys are the latest innovation in healthcare science that provide the health benefits of kidney transplantation and potentially wipe out the need for dialysis. Powered by silicon nanotechnology, artificial kidneys seek to eliminate the torture faced by dialysis patients and may prove to be a boon to patients with acute renal failure.

In a new development, the Kidney Research Institute of the University of Washington is currently developing a wearable artificial kidney that is expected to go into clinical trials in 2022. This could be a game changer in the medical devices sector, and may reduce the dependency on dialysis equipment to a great extent.

Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-711

Dialysis Continues to Remain Dominant Therapy to Treat ESRD

While developments in the global healthcare sector continue to focus on innovative products and therapies, dialysis is currently the most administered treatment option for ESRD. Dialysis equipment is in great demand in hospitals, clinics, and dialysis centres across the world, boosting demand in the global market. According to a recent research study published by Future Market Insights, the global dialysis equipment market is projected to register a CAGR of 4.8% and will likely reach a valuation of US$ 23.6 Bn by 2028 end. The medical sector meanwhile continues to introduce newer dialysis equipment in the global market to address the varied needs of patients.

Portable Home Dialysis Equipment Trending the Global Market

Home dialysis has remained a preferred option for patients with renal disease as it is more convenient and less expensive than hospital based dialysis. Leading medical devices manufacturer Quanta has recently launched advanced haemodialysis equipment with an objective to improve the lives of patients requiring dialysis on a regular basis. This is an extremely flexible dialysis treatment that patients can take in the comfort of their homes. Quanta’s home dialysis equipment is portable, lightweight, and very easy to use. This dialysis equipment also incorporates advanced technology such as high-res screens with touchscreen functionalities and helps enhance patient outcomes.

Manufacturers of dialysis equipment are developing fully automatic, portable, and advanced dialysis equipment to treat patients of all ages suffering from ESRD. A notable technological advancement includes the introduction of high-efficiency and high-flux membranes, enabled by technical advances in membrane technology and polymer chemistry. Unlike traditional renal replacement machines, automated dialysis equipment facilitates the management of disease parameters digitally, thereby ensuring more accuracy and reducing costs of labour.

Wearable Dialysis Equipment to Ease Patient Discomfort; Expected to Rule the Global Market

With technology having proliferated every aspect of human lives, the innovation of wearable dialysis equipment is a blessing for countless dialysis patients, who can now break the shackles of confinement to fixed dialysis equipment and enjoy increased mobility. Wearable dialysis equipment is a miniature artificial HD machine based on dialysate regenerating sorbent technology. Designed for use as a belt, patients can wear this dialysis equipment for slow, gentle dialysis. This dialysis equipment is touted to best mimic the natural kidney function of blood cleansing. Given the continuous advancements taking place in medical device technology, wearable dialysis equipment may soon emerge in a more compact and small form factor to provide increased convenience and usability to patients.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-711

Miniature artificial kidneys could redefine the entire ecosystem of dialysis treatment. The integration of portable home haemodialysis equipment facilitating elongated use in homes and offices with wearable artificial kidneys for peritoneal dialysis allowing uninterrupted blood cleansing throughout the day will ensure more patient comfort and guarantee better and enhanced performance of the dialysis equipment.

[fmihealthcare-blog]

Pharmaceutical Intermediates Market is expected to expand at 4.5% CAGR in 2029

                        Global sales of pharmaceutical intermediates closed in on US$ 26 billion 2018, which is likely to see modest Y-o-Y growth in 2019, by an estimated 3.6% rate. More than 70% of the pharmaceutical intermediates consumed, were generic. A moderate demand growth outlook has been projected for branded pharmaceutical intermediates.

Prominently driven by high sales of chiral intermediates, bulk drug intermediates will continue to account for over 3/5th of overall sales, followed by chemical intermediates. The report highlights pivotal role of CROs (contract research organizations) and CMOs (contract manufacturing organizations) in shaping the pharmaceutical intermediates market, as they collectively contribute more than 60% to the market value. Pharma and biotech companies are also likely to develop as key end users of pharmaceutical intermediates in the near future.

Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-4515

Application in Analgesics Account for a Third of Global Revenue

Increasing prevalence of the chronic diseases, coupled with the improved rate of early diagnosis, is heavily contributing to the towering drug demand. The report opines that prevalence rate of CVDs (cardiovascular diseases) and diabetes will particularly bolster pharmaceutical intermediates consumption. Over 1/3rd of the pharmaceutical intermediates market revenues is accounted by application in analgesics, followed by cardiovascular drugs and oral antidiabetic drugs, as reported by the study.

Moreover, the increasing rate of seeking treatment is also likely to boost the demand for drugs. According to the report, global pandemics, such as H1N1, Ebola, and others are also accounting for fostering drug demand – thereby pushing consumption of a wide range of APIs and pharmaceutical intermediates.

Manufacturing Companies to Strategize on Increasing Drug Approvals

A couple of years ago, the Center for drug evaluation and research (CDER) approved more than 45 novel drugs, compared to 22 in 2016. The average novel drug approval each year, is around 31 and, and thus FMI’s analysis finds that the year 2017 witnessed a significant rise in the number of drug approvals. With the number of drug approvals on a constant rise, it is highly likely that the demand for pharmaceutical raw materials such as pharmaceutical intermediates and APIs will also witness gains in the years to come.

To cater to billowing demand in drug formulations, a number of players prominently active in the global pharmaceutical intermediates landscape are maintaining focus on expanding production capacity. Merck KGaA, for an instance, has announced production capacity expansion in Aubonne, Switzerland. The new production facility is supposed to be fully functional by the end of 2023, as reported. The production capacity will be enhanced by over 50% of the existing.

Pharmaceutical intermediates manufacturers seeking cGMP (Current Good Manufacturing Practice regulations) approval from various western regulatory bodies. Key manufacturers of pharmaceutical intermediates, particularly those based in the East and South Asian regions, are focused on their efforts in gaining FDA or EMA (European Medicine Agency) regulatory approvals for their manufacturing plants.

FMI’s research marks that the production costs associated with pharmaceutical intermediates, APIs, and final drug formulations is around 50-60% less when based in emerging Asian markets, compared to that in North America and Europe. This cost benefit according to the report will continue to attract foreign investments from pharmaceutical and biopharmaceutical companies based in overseas. On the other side, leading exporters of pharmaceutical intermediates are focusing on blending the lower production costs and high quality.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-4515

The report tracks some of the key companies operating in the Pharmaceutical Intermediates market, including Chiracon GmbH, Aceto Corporation, Midas Pharma GmbH, BASF SE, Codexis, Inc., A.R. Life Sciences Private Limited, Dishman Group, ZCL Chemicals Ltd., Pfizer, Inc., Arkema Inc and Cambrex Corporation among others.

[fmihealthcare-blog]

Prothrombin Complex Concentrates Market is expected to expand at 4.5% CAGR in 2028

                     A new study by the company titled 'Prothrombin Complex Concentrates Market: Global Industry Analysis 2013–2017 and Opportunity Assessment 2018–2028', has listed out the key points being considered by the companies operating in the prothrombin complex concentrates market to emerge and stay sustainably profitable in the long run. The North America prothrombin complex concentrates market is projected to expand at a CAGR of 3.5% over the forecast period. North America and Western Europe are expected to be dominant markets for prothrombin complex concentrates, as most of the manufacturing facilities of prothrombin complex concentrates are located in these regions. However, the increasing demand for optimized & sustainable healthcare in countries of Asia Pacific, such as China and India, and of Middle-East is expected to fuel the growth of the prothrombin complex concentrates market.

The report finds the players operating in the market are laying emphasis on improving treatment options for patients with hemophilia B. Treatment with prothrombin complex concentrates is an economical option for warfarin reversal. It is has been observed that the treatment with prothrombin complex concentrates is the most economical option as it minimizes the hospital stay and laboratory costs. Direct healthcare costs including drug and hospital costs in Europe are approximately US$ 400,000 for prothrombin complex concentrates, whereas for warfarin withdrawal therapy, it was approximated US$ 1,200,000.

Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7032

Manufacturers tend to depend on plasma as a primary precursor to manufacture prothrombin complex concentrates, and in the past, they relied on third-party sources for plasma. Manufacturers are now opening their own plasma collection banks to reduce dependence on third-party sources. This trend has been observed to have grown since 2013. The key players operating in the market, such as CSL Behring & Shire, have scaled up their focus on depending on their own sources for plasma.

Compound pharmacies, retail pharmacies, and hospital pharmacies distributing prothrombin complex concentrates are the primary point of contact for patients experiencing hemophilia B and other disorders. The hospital pharmacies segment in the prothrombin complex concentrates market accounted for over 40% revenue share in 2017. The growing demand for cost-effective diagnostic options is also expected to propel the growth of the global prothrombin complex concentrates market over the forecast period.

The manufacturers of prothrombin complex concentrates are particularly focusing on acquisitions, collaborations, and opening plasma banks, where joint collaboration with various organizations is the prime activity to spread awareness regarding the efficiency of prothrombin complex concentrates.

The growing geriatric population & unmet hemophilia therapeutic needs are also expected to be important factors fueling the growth of the prothrombin complex concentrates market over the forecast period. The worldwide incidence of hemophilia is not well known and it is estimated that 75% of people with hemophilia receive inadequate treatment or have no access to the treatment. The growth in the global population over 65 years of age is expected to be the high impact driver for the growth of the market. As per the U.S. Census Board, around 13% of the U.S. population is above 65 years old and this figure is estimated to touch 20 % by the end of 2030.

Development of prothrombin complex concentrates and commercial production are highly intricate and complex. Prothrombin complex concentrates are prepared from pooled plasma. They pose a theoretical risk of transmitting infectious agents, which might survive the extraction and attenuation steps during the manufacturing process. There is a lack of substantial clinical evidence on contraindications and exclusion criteria, which is expected to hinder the growth of the prothrombin complex concentrates market over the forecast period.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-7032

Examples of some of the key participants operating in the prothrombin complex concentrates market analyzed in this report are Shire, Octapharma AG, Nihon Pharmaceutical Co Ltd, Sanquin Blood Supply Foundation, CSL Behring GmbH, Kedrion Biopharma Inc, and Grifols, S.A.

[fmihealthcare-blog]

Frontotemporal Disorders Treatment Market to Display Growth at a CAGR of 4.7% in 2028

                        With the severe dearth of FDA-approved drugs in the reliable treatment of frontotemporal disorders, frontotemporal disorders treatment continues to underscore the growing significance of disease management. As frontotemporal disorders treatment exclusively includes symptomatic efforts till date, the condition continues to attract research interests worldwide.

The available drugs and other means of frontotemporal disorders treatment do not stop or even decelerate the frontotemporal disorders progression, which further remains a key driving force for the growing demand for frontotemporal disorders treatment.

Frontotemporal disorders are often misdiagnosed as depression, Parkinson’s, Alzheimer’s, or any other psychiatric condition, thereby limiting the scope of adoption of frontotemporal disorders treatment.

Although clinical trials have been producing a number of interventions other than medication, a consistently high rate of clinical trial failure is cited as a significant factor influencing the prospects of frontotemporal disorders treatment in the near future.

Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5033

The report highlights the critical role of governments as well as non-governmental non-profit organizations in terms of research grants and drug approvals. Expanding incentives for orphan drug development is identified as a prominent factor pushing the revenue growth of frontotemporal disorders treatment landscape.

Demonstrating a moderate growth in the revenue year on year, the global landscape of frontotemporal disorders treatment market is slated to approach the US$ 3 billion mark in 2019. As presented in a newly published research intelligence on the global market scenario of frontotemporal disorders treatment, the revenue growth is predominantly driven by the progressing pace of clinical trials.

Discussing the revelations made by the study, says a senior research analyst at Future Market Insights says, “Although frontotemporal disorders are referred to as a symptomatic condition that has not witnessed a curative treatment as of now, an extensive clinical research targeting the discovery of breakthrough curative treatments is driving the growth of revenue at a steady rate”.

Strategic Collaborations Are Shaping the Competition in Fragmented Market

In a highly fragmented landscape of the global frontotemporal disorders treatment market, almost 70% of the companies offer generics as their key drug offerings. Operated by a large number of prominent international, multinational, and regional players, the market for frontotemporal disorders treatment is recently witnessing a heap of strategic deals, including acquisitions, collaborations, and alliances.

2017 was a year of partnerships for GlaxoSmithKline Plc. The company entered multiple strategic collaborations with giants such as Google and Alimama for improved marketing and advertising results. Further, with an objective to push the new drug discovery platform, GSK also signed a four-year contractual partnership with 23andMe. This deal is more likely to speed up the overall clinical progress in frontotemporal disorders treatment.

Moreover, several companies are constantly taking efforts in introducing new potential drugs post successful clinical trials, in the existing line of frontotemporal disorders treatment.

AstraZeneca plc. has recently inked an agreement with Luye Pharma Group, Ltd. over the licensing and sales of Seroquel and Seroquel XR across China, and the UK, in addition to a few other international markets. The drug is occasionally used to address a set of behavioral problems associated with FTD.

According to the taxonomy analysis of frontotemporal disorders treatment market presented in the report,

Cognitive enhancers are currently contributing around 80% share in the total market value, securing the position of the most favored drug class incorporated in the treatment of frontotemporal disorders.

On the other side, behavioral symptom management remains the most preferred type of treatment for patients of frontotemporal disorders, thereby accounting for nearly 60% share of the revenue generated in the global frontotemporal disorders treatment market.

An extensive analysis of the frontotemporal disorders treatment landscape uncovers that around half of the market value belongs to the retail pharmacy segment, making it the most popular distribution channel for frontotemporal disorder drugs.

Hospital pharmacies remain the second largest channel of distributioni in the frontotemporal disorders market, says the report.

Frontotemporal Dementia Is Highly Prevalent

Based on the symptomatic indication, frontotemporal dementia (FTD), holding a massive market value share, remains the most common indication among all that continues to capture maximum clinical research interests.

Industry experts project that the rapid development of new FTD therapies will push collaborative activities among clinical research entities, educational institutions, academic laboratories, pharma and biotech centers, and the FDA.

Furthermore, FTD therapeutics are anticipated to witness a major contribution from pharmaceutical companies – eventually boosting the funding and clinical trial scenario.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-5033

Western Europe Accounts for the Lion’s Share in Market Value

Western Europe and North America collectively extend more than 55% share in the total market value, the former's share is however projected to remain higher over the foreseeable future. APEJ, with an attractive revenue contribution at present, is projected to remain a highly lucrative regional market for potential investors in the frontotemporal disorders treatment landscape.

While rapidly growing FTD prevalence and the expanding ongoing clinical trials platform are providing a collective push to frontotemporal disorders treatment market in Western Europe, research estimates rapid emergence of Asian economies owing to increasing sophistication of the region’s healthcare sector and gradually surging awareness about frontotemporal disorders.

[fmihealthcare-blog]

Oral Clinical Nutrition Supplements Market to Display Growth at a CAGR of 6.1% in 2026

Demand for oral clinical nutrition supplements continues to surge, with global revenues set to witness impressive growth in 2019, according to a new research study by Future Market Insights (FMI). Gains continue to be driven by steady sales in Europe and the US, however, manufacturers are eyeing lucrative opportunities in Asia Pacific, where a newfound focus on health and wellness is driving demand. Future Market Insights’ study remains bullish on the long-term prospects of oral clinical nutrition supplements market.

Highlighting the key driving factors, the report opines that increase in the number of millennial and baby boomers is creating opportunities for market players. The geriatric population suffers from multiple health issues such as digestion, acidity, and metabolic health issues. Across the globe, over 50% geriatric population is suffering from these disorders, and oral clinical nutrition supplements are usually recommended as a form of management.

The trends in oral clinical nutrition supplements market mimic the broader trends in the nutrition supplements market. Poor dietary patterns and consumption of junk foods have meant that consumers often have to include supplements in their daily intake. Further, doctors and healthcare providers are prescribing oral clinical nutrition supplements to patients who develop symptoms due to low intake of essential nutrients. These factors are likely to provide an impetus to the growth of oral clinical nutrition supplement market in 2019 and beyond.

Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/REP-GB-9486

According to the study, demand for oral clinical nutrition supplements is also increasing on account of growing focus on managing obesity. A significant percentage of population in the US, Europe, and Asia Pacific can be considered obese, and growing emphasis on maintaining a healthy dietary intake has led to growing consumption of dietary supplements. The study finds that growing consumer focus on maintaining ideal weight will provide the much-needed impetus to the growth of the market.

Oral clinical nutrition supplements are available in the market with unique flavors such as chocolate, vanilla, strawberry, apple, mixed barriers, orange, almond and nut flavors, etc.  Oral clinical nutrition supplements are available product offerings such as yogurts, mayonnaise, juices, energy drinks, soups, and desserts. The availability of clinical nutrition supplements in powdered form which can be added in food and beverage like coffee, tea, milk, custards, and cereals has also meant that consumers have a wider flexibility to choose from. The variety of oral clinical nutrition supplement products and unique flavors are attracting consumers towards oral clinical nutrition supplement.

The study finds that oral clinical nutrition supplement market is also supported by favorable government initiatives. Many governments and healthcare providers are offering a free oral clinical nutrition supplement to underprivileged children. These initiatives have provided sustained opportunities to stakeholders in the oral clinical nutrition supplement market.

This report on oral clinical nutrition supplement covers the trends driving each segment, and offers analysis and insights into the potential of the clinical nutrition supplement market in specific regions. According to the study, growth of the oral clinical nutrition supplements market in North America and Europe will be supported by steady gains in Asia Pacific.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-9486

The report also profiles the business and product strategies of some of the leading players in the oral clinical nutrition supplement market. The key players profiled in the oral clinical nutrition supplement market include NUTRICIÓN MÉDICA SL, Meiji Holdings Co., Ltd, Medtrition Inc., Baxter International Inc., B. Braun Melsungen AG, Fresenius Kabi AG, Mead Johnson & Company, LLC, Otsuka Pharmaceutical Europe Ltd, Abbott Laboratories, Danone Nutricia, Victus, Inc., Cambrooke Therapeutics, Inc, GlaxoSmithKline plc, Nestlé S.A., Kate Farms, Inc., Perrigo Company plc, Sichuan Kelun Pharmaceutical Co.Ltd, AYMES International Ltd, Pfizer Inc, Medifood GmbH, Nature’s Bounty Inc, Pharmavite LLC, Bayer AG, Church & Dwight Co. Inc.

[fmihealthcare-blog]

Venous Thromboembolism Treatment Market will expand at healthy CAGR of 4% in 2029

The global demand for venous thromboembolism treatment market is likely to grow steadily over the forthcoming years. As indicated by a recent Future Market Insights (FMI) study, the market revenues will observe approximately 4% CAGR between 2019 and 2029. More than 3/5th of treatment demand is underpinned by deep venous thrombosis, according to the report. Catheter-directed thrombolysis devices and percutaneous thrombectomy devices, collectively account for more than half of the global revenues represented by the venous thromboembolism treatment market.

Venous thromboembolism treatment involves segmented pneumatic compression pumps without gradient, segmented pneumatic compression pumps with calibrated gradient, lower pneumatic compression sleeves, non-segmented pneumatic compression pumps permanent inferior vena cava filters, retrievable inferior vena cava filters, embolectomy balloon catheters, percutaneous thrombectomy devices, catheter-directed thrombolysis (CDT) devices and upper pneumatic compression sleeves. Based on the disease indication, deep vein thrombosis is expected to hold a prominent share in the overall venous thromboembolism treatment market                                                                                                                                                        

                                   Poor Reimbursement Scenario Against High Treatment Costs to Restrict Adoption

Several factors are impacting the overall growth of the venous thromboembolism treatment market. The first and the most important factor driving the venous thromboembolism treatment market is the increasing prevalence of venous thromboembolism disease. Other factors, such as the increasing retrieval rate of vena cava filters, increasing healthcare awareness, presence of favourable reimbursement policies, and increasing geriatric population, are also responsible for the growth of the venous thromboembolism treatment market.

Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1341

Apart from the driving factors of venous thromboembolism treatment market, there are few factors that are likely to hinder the overall growth of the venous thromboembolism treatment market. The high cost associated with venous thromboembolism treatment therapy, poor reimbursement for some of the treatment devices, and poor insurance support are among the major factors that are expected to hamper the growth of the venous thromboembolism treatment market.

Drug-based Treatment Witnessing Traction across Europe

Although increasing preference for drug-based venous thromboembolism treatment is highly likely to hinder the growth of the market, new-generation drugs, including non-Vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban, are estimated to boost the adoption rate of venous thromboembolism treatment due to increased efficacy. However, there are regional variations to this trend.

North America is expected to be a prominent region in the global venous thromboembolism treatment market because of the presence of a well-developed healthcare infrastructure and numerous technological advancements in the region. The increasing prevalence of venous thromboembolism is also responsible for the boosting the growth of the North America market. Treatment using mechanical and interventional prophylaxis systems is expected to be increasingly adopted in the North American region during the forecast period. In addition, drug-based treatment is expected to gain popularity in the European region, which is expected to subsequently decrease the usage of mechanical and interventional treatments in the region.

On the other hand, increasing per capita healthcare expenditure is one of the macroeconomic factors that is likely to boost the market. Nowadays, certain changes in the socio-economic scenario can also lead to significant growth in the venous thromboembolism treatment market.

Tier 1 Players Account for Nearly 35% Market Revenue Share

Some of the key manufacturers of venous thromboembolism treatment are mainly focusing on innovating and launching new and advanced products. Major players in the venous thromboembolism treatment market are focusing on collaborations and acquisitions. For example, venous thromboembolism treatment is majorly adopted by hospitals, catheterisation laboratories, and ambulatory surgical centres. Hospitals are expected to hold a significant revenue share in the venous thromboembolism treatment market.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-1341

The report tracks some of the key companies operating in the venous thromboembolism treatment market such as ArjoHuntleigh AB, AngioDynamics, Cardinal Health Inc., BTG International Ltd., Stryker Corporation, DJO Global Inc., EKOS Corp, and Teleflex Inc., Boston Scientific Corp.  There are several other companies operating in the venous thromboembolism treatment market. AngioDynamics, Boston Scientific Corp., and Cardinal Health Inc. are expected to hold a prominent share in the venous thromboembolism treatment market. These tier 1 companies hold a share of approximately 35% in the venous thromboembolism treatment market.

[fmihealthcare-blog]

Mucopolysaccharidosis (MPS) Treatment Market will expand at a healthy CAGR of 6% by 2029

A market study presented by FMI ' Mucopolysaccharidosis Treatment Market: Global Industry Analysis 2014-2018 and Opportunity Assessment 2019-2029,' explains the significant factors influencing the current market structure.

According to research, the mucopolysaccharidosis treatment is still emerging, and different geographies have implemented standard treatment options for the condition. However, there is no universally accepted treatment pattern for mucopolysaccharidosis. Mucopolysaccharidosis falls under rare diseases, which is a complex, diverse, constantly evolving field, and there is a significant shortage of medical and scientific data related to it. Mucopolysaccharidosis treatment and diagnosis involves complex managing requirements, which include long-term care, rehabilitation support, and a continuous treatment plan.

               Research Activities Uplift Stem Cell Therapy Application in MPS Treatment

In the present scenario, the drugs that are considered for mucopolysaccharidosis treatment, such as aldurazyme, naglazyme, vimizim, elaprase, mepsevii and hunterase, are the only regulated and recommended drugs present in the market. These drugs fall under enzyme replacement therapies, however, with present research initiatives for stem cell therapies, the latter is considered a prominent mucopolysaccharidosis treatment. Clinical research shows that stem cell transplantation covers a large area that is not covered with the more frequently recommended practice of enzyme replacement therapies, which changes the current market structure for mucopolysaccharidosis treatment, prioritising the latter.

Stem cell therapy is a therapeutic option for mucopolysaccharidosis patients suffering from a severe phenotype, as research shows the method can preserve neurocognition or can even help break the progressive neurodegeneration. The method is provided with strict selection criteria, which is followed by maintained regulations. Research shows that stem cell therapy as a treatment option is gaining popularity among healthcare professionals for mucopolysaccharidosis treatment, which can be attributed to the relation of its better reach towards a normal health condition for the patient.

Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5880

Enzyme Replacement Therapy Remains Lucrative for Market Investors

As per further assessments of the mucopolysaccharidosis treatment market, it has been difficult to collect epidemiological data pertaining to rare diseases, especially mucopolysaccharidosis treatment, which is likely to impede the actual estimation of the economic burden associated with the condition. The cost estimation for each mucopolysaccharidosis treatment type is affecting and, in turn, creating a more vulnerable situation for the businesses and disrupting research & development activities for each company.

Enzyme replacement therapy is the most attractive segment for investors, however, the unavailability of reimbursement plans and precise treatment plans is encouraging most patient in developing regions to opt for symptomatic treatments instead of enzyme replacement therapy, which is still considered to be the standard mucopolysaccharidosis treatment.

Key Players Focus on Clinical Research of Treatment Models

The report segments the mucopolysaccharidosis treatment market into seven regions to elaborate on the regional trends pertaining to the treatment plan. Major players are focusing on increasing their market share in the Asia Pacific market through strategic collaborations with regional research institutes. There is a lack of awareness about rare diseases among the general public as well as in medical healthcare facilities in several emerging economies. According to a survey and industry report, it takes patients in the US an average of 7.6 years and patients in the UK an average of 5.6 years to actually receive a proper diagnosis. Moreover, it involves a team of healthcare professionals to actually get the right mucopolysaccharidosis treatment and diagnosis pattern for reported cases.

Manufacturers are in the process of introducing a considerable number of mucopolysaccharidosis treatment options, which are currently under clinical trials. An estimated 160 and above clinical trials are being performed for mucopolysaccharidosis treatment. Thus, ensuring that the manufacturers take this mucopolysaccharidosis treatment market to be lucrative and potential rich in terms of revenue. Medical research institutes play an important role in this particular market. They are expected to be the bridge between treatment plans and economical solutions for manufacturers, thus leaving an explicable and lucrative model for mucopolysaccharidosis treatment.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-5880

The mucopolysaccharidosis treatment market includes companies such as BioMarin Takeda Pharmaceutical Company Limited, Sanofi S.A., and Ultragenyx Pharmaceutical Inc. BioMarin accounts for a significant value share in the present mucopolysaccharidosis treatment market. The currently existing promising drug types are expected to face competition from emerging candidates. In addition the mucopolysaccharidosis treatment products of other companies, such as Sangamo Therapeutics, Inc., REGENXBIO Inc., Sarepta Therapeutics, Abeona Therapeutics, Inc., and others, are also in the pipeline.

[fmihealthcare-blog]

Medical Physics Market to expand at a healthy CAGR of 6.4% over 2018-2028

                 According to the latest research by Future Market Insights (FMI), the global market for medical physics will exceed the valuation of US$ 6 billion towards the end of projection period.

Prominently driven by the growth of medical tourism sector and increasing expanse of diagnostics, the global revenue of medical physics market will reportedly thrive at a healthy over-6% CAGR during 2018-2028. Growing adoption of nuclear medicine has also been cited as an important factor responsible for a positive growth outlook anticipated for medical physics market.

However, the report also highlights that the insufficient availability of skilled workers and relatively poor healthcare infrastructure for medical physicist trainings in developing regional markets will continue to restrict penetration of medical physics in the long run.

Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5274

The ‘Outsourcing’ Trend Is Creating Firm Base for Merger & Acquisition Strategies

With the consolidation of hospitals, there is an increasing need for larger firms in the medical physics market, with an intent to handle the outsourced services so as to contract with fewer services providers. The medical physics market is characterised by the presence of small independent companies, and there is a negligible number of large-scale operators. According to the report, this presents opportunities for private equity firms to enter the middle-market platform and scale-up their medium-scale operations to large-scale operations through the acquisition of smaller firms.

Other factors driving mergers and acquisitions in the medical physics market include increasing stringent regulations and an increasing number of owners looking to exit the medical physics business. Increasing stringent regulations have resulted in the inspection of a larger number of machines and associated elements. Several healthcare systems are incurring higher risks due to the increasingly stringent regulations. This opens opportunities for medical physics companies to ensure compliance and reduce operation cost by outsourcing. Furthermore, most of the medical physics firms are owned and operated by baby boomers who are about to retire from their medical physics business. For a majority of those medical physics service providers who are retiring, selling their business has been considered to be the most preferred option.

Some of the other trends in the medical physics market include increased outsourcing by healthcare providers, increasing number of independent diagnostic imaging centres, and advancements & adoption of technology across the world.

Segmental Insights: Medical Physics Market: Diagnostic modality, driven by increasing adoption of diagnostic procedures such as PET, SPECT, CT, and MRI, will continue to account for more than 65% share of the total medical physics market value.

Based on services, accreditation assistance is slated to remain dominant, followed by safety surveys. The report anticipates physics testing and regulatory and auditing services to emerge highly potential.

Following hospitals, diagnostic imaging centers are likely to register significant adoption rate in the medical physics market through 2027.

The North American and European medical physics market will reportedly account for a majority of market value, according to FMI’s analysis on medical physics market. The report has attributed this dominance to rapid consolidation of healthcare facilities in these regions.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-5274

Some of the key players in the medical physics market include Krueger-Gilbert Health Physics, Inc., LANDAUER, Medical Physics Services, Medical Physics Services Consultants, Inc., Alyzen Medical Physics Services, Radiation Safety & Control Services, Inc., Upstate Medical Physics Services, Dade Moeller & Associates, Versant Medical Physics Services & Radiation Safety, Alliance Medical Physics Services  LLC, West Physics Consulting, LLC, Associates in Medical Physics Services, Radiation Services, Inc., Jaeger Corporation, and Petrone Associates, LLC.

[fmihealthcare-blog]

Upper Limb Prosthetics Market will expand at healthy CAGR of 4.8% in 2028

Upper limb prosthetic sales in 2019 are estimated to close in on US$ 330 Mn, and record a Y-o-Y growth of 4.4% over 2018, according to a new study of Future Market Insights (FMI). Upper limb prosthetics have been witnessing progressing sales scenario at a modest pace over the recent past. Besides a rising trend of cosmetic prosthetics, prevalence of sports injuries is significantly contributing to the demand growth of upper limb prosthetics in the global market.

Use of additive manufacturing/3D printing for prosthetics has been gaining momentum within the marketplace, particularly among amputees who are unable to afford the high price point associated with conventional limb prosthetics. Adoption of upper limb prosthetics has been pervasive at hospitals, at a steadily increasing rate. FMI expects a higher rate of adoption across prosthetic clinics in the years to come. However, an expensive price point, coupled with mass production incompatibility, is most likely to limit rapid revenue growth of upper limb prosthetics market.

Several prominent players in the competitive landscape of upper limb prosthetics market are prioritizing new product launches eyeing the opportunities lying in competitive price ranges. While this strategy is likely to aid companies improve penetration into developing markets, others will also focus on development of convenient accessories to assist the usage of upper limb prosthetics – such as hand gloves.

Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8991

As per FMI’s analysis, a considerable number of companies competing in upper limb prosthetics market are concentrating on providing rehabilitative prosthetic services and amputee care. Consistently increasing demand for prostheses following accidental and aging related disabilities will primarily push sales of upper limb prosthetics. Rapid surge in the number of orthopedic disorders and post-traumatic disabilities will also remain a key factor determining demand for upper limb prosthetics in the near future, according to the report.

Prosthetic Wrist to Hold over One-Fourth Market Share

Transradial disarticulation (below elbow) will remain the key indication generating maximum demand for upper limb prosthetics. The report points to a higher revenue share of over 1/4th of the total value, collectively contributed by wrist disarticulation and transhumeral disarticulation (above elbow). Sale of partial hand has also been registering a moderately growing share in the market revenue.

Prosthetic wrist sales account for over a fourth of the total market value whereas, prosthetic arm is likely to develop highest-selling potential in the years to come. Prosthetic elbow and terminal devices are currently among highly sought after components of upper limb prosthetics after prosthetic wrist, according to FMI’s study. The combined revenue share of these two in the market has been anticipated to be more than 45% in 2019. However, prosthetic shoulders will also continue to experience moderate demand over the course of next few years.

Almost 2/5th of the total demand for upper limb prosthetics is accounted by myoelectric prosthetic devices, followed by body powered counterparts. As per FMI’s analysis, passive prosthetic devices can be positioned as a relatively lucrative type of upper limb prosthetics.

North America & Europe Hold over 55% Share in Market Value

While more than 55% share of the global market revenue is contributed by developed regional markets, the penetration of upper limb prosthetics within most of the developing regions remains in its latency. According to FMI’s study, the market in China, India, and some of the fast-developing economies in East and South Asia economies hints at promising growth prospects post 2019. The report attributes this growth to the sophistication of healthcare infrastructure, improvements in reimbursement scenario, rapid expansion of the patient pool, and the flourishing medical tourism sector.

Increasing per capita healthcare spending, spike in the private and public investments in R&D, and the influx of activities involving shifting of manufacturing bases to developing regional pockets have also been instrumental in establishing a positive growth outlook for upper limb prosthetics market in these regions.  

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-8991

FMI forecasts a 4.8% CAGR for the upper limb prosthetics market revenue over 2018-2028. The report has tracked some of the most prominent players active in the global upper limb prosthetics market, including Fillauer LLC, Touch Bionics Inc., Endolite India Ltd., College Park Industries, and Ottobock SE & Co. KGaA, among others.

[fmihealthcare-blog]

Sleep Aid Devices Market Value is expected to US$ 29,200 Mn by end of 2026

Demand for sleep aid devices is widely prevalent, owing to the increasing sleep disorders such as insomnia, obstructive sleep apnea, and central sleep apnea. Severe side effects of sleeping sedatives such as allergy, hypnotics, hematologic reactions, and hepatotoxic, have influence the individuals to favor sleep aid devices over sleeping pills.

There has been a significant surge in the demand for sleep aid devices ascending from the rising geriatric population, by the dent of insomnia being common in this demography. Pervasiveness of polypharmacy and multimorbidity in the elderly population have a strong impact on their sleeping patterns, which is further anticipated to drive the growth of sleep aid devices. Comorbidities such as type 2 diabetes, obesity, stroke, heart diseases, and atherosclerosis, along with the diseases caused by smoking, drug abuse, and alcohol have affected the sleep of individuals.

With the considerable rise in the disposable incomes of the individuals, affording these sleep aid devices is possible for the consumers. This in turn, offers a lucrative growth opportunity to the sleep aid devices market at the global level. A host of these factors have contributed to the affluent growth of sleep aid devices market, which is projected to clock an impressive CAGR of over 4% by the end of 2026.

A Sample Of This Report Is Available Upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8956

Increasing Awareness of Disorders Pertaining to Sleep is Anticipated to Trigger the Growth of Sleep Aid Devices Market

Various government & non-government groups like Circadian Sleep Disorders Network & American Sleep Apnea Association (ASAA) are organizing numerous programs for increasing awareness of the significance of sound sleep and the utilization of sleep aid devices. Another centralized organization, National Sleep Foundation dedicated an entire week by celebrating sleep cognizance week, in the bid to create cognizance of sleep disorders.

Such thoughtful initiatives taken by the government and private organizations have contributed to the growing inclination of people towards sleep aid devices. On the back of these factors, the global sleep aid devices market is growing at an accelerated pace.

Mergers and Acquisitions Prevailing in Sleep Aid Market to Fortify the Growth of Sleep Aid Devices Market

Key insights derived from the report comprises of an incisive view of the leading players working towards transforming the existing scenario of sleep aid devices market. The report profiles players such as ResMed Inc., Sleep Number Corporation, Koninklijke Philips N.V., Responsive Surface Technology LLC, Simmons Bedding Company LLC, Eight Sleep Inc., Electromedical Products International, Inc., Ebb Therapeutics, Sleepace Inc., Kingsdown, Inc., Drive DeVilbiss Healthcare LLC, SleepMed Inc., Cadwell Laboratories Inc., Teva Pharmaceutical Industries Ltd., Drive Medical Ltd., and RESPeRATE.

Key players such as Tempur Sealy International, Simmons Bedding Company LLC., Sleep Number Corporation, Dreams, ResMed, and Koninklijke Philips N.V. enjoy a significant share in the global sleep aid devices market. These players are putting their efforts into developing new products and diversifying their portfolio in sleep aid devices market. With a view to expanding their operations, manufacturers of sleep aid devices market are collaborating with retailers, distributors, and local wholesalers.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-8956

Regional players are competing in sleep aid devices market on the basis of their even distribution of channel and pricing of sleep aid devices. On the contrary, the leading players in sleep aid devices market are focusing on effective marketing strategies to increase the penetration of their product. Strategic mergers and acquisitions happening in sleep aid devices market have been a robust growth driver for the sleep aid devices market. Recent developments and business strategies adopted by these leading firms are projected to fortify the growth of the global sleep aid devices market by 2026 end. A decisive view on each of these players and their participation in the global sleep aid devices market growth is encapsulated in the report.

[fmihealthcare-blog]

Over-the-Counter Pain Medication Market to Display Growth at CAGR 4.0% through 2028

                 Advancements in Pain Management and the Rising Prevalence of Acute Pain

The rising prevalence of lower back pain, neck pain, headache, migraine, and other acute pain conditions is boosting the market for over-the-counter pain medication. According to a survey conducted by the National Center for Biotechnology Information, over 80% of the population experiences episodes of acute pain conditions in their lifetime due to continuous sitting, sports and activities, sudden falls, other health conditions, lifestyle, hygiene, etc. The expansion of companies offering novel and cost-effective over-the-counter pain medications in Asian countries is expected to fuel the growth of the over-the-counter pain medication market. Companies having patent rights for particular over-the-counter pain medication are targeting potential countries in Asia and Africa. For this purpose, these companies are seeking the approval of respective government authorities in view of commercializing their products. Increased efforts by manufacturers to offer cost-effective over-the-counter pain medication and rapid advancements in pain management are expected to boost the over-the-counter pain medication market.

Severity of Abusive Over-the-Counter Pain Relief Drugs

The popularity of over-the-counter pain medication increases the potential of its abuse. It has been observed that some over-the-counter pain medication are being overused, consumed in larger quantities than what is prescribed, and sometimes, patients became addicted to them. Due to these factors, patients suffer from adverse effects. Most over-the-counter pain medications are safe for healthy people only if used as directed. The most commonly used over-the-counter pain medication for relief are non-steroidal and anti-inflammatory drugs, which can cause potentially fatal adverse effects such as stomach bleeding and ulcers. According to the American Gastroenterological Association, in the U.S., more than 30 Mn people are using NSAIDs every day for pain relief from headaches, backache, arthritis, and other acute conditions. It has been observed that there is a lack of proper guideless and awareness among a large percentage of the population regarding the dosage of over-the-counter pain medication and the manner in which they should be taken. A large number of patients are consuming acetaminophen for almost all types of chronic and acute pain, and thus suffering from its adverse effects and predisposing themselves to serious complications associated with ill self-diagnosis and self-medication.

A Sample Of This Report Is Available Upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8947

Growth in Aging Population Suffering from Pain Disorders

The growing aging population is at a high risk of chronic pain disorders. During the aging process, several physical changes take place, which can impact the processing of pain among the population of this age group. Pain occurs due to several reasons such as reduced mobility, falls, and evasion of activity, sleep impairment, anxiety, and depression. In the United States, the Institute of Medicine stated that the prevalence of pain has been increasing among all age groups, but has been consistently the highest among the aging American population. The aging American population has the highest long-term consumption rate of over-the-counter pain medication for pain relief. In addition, the increase in the prevalence of age-related pain disorders is boosting the usage of over-the-counter pain medication among the elderly population. This age group is the major target group for manufacturers, and is contributing to the growth of the over-the-counter pain medications market. This growing patient pool will boost the growth of the over-the-counter pain medication market during the forecast period.

Adverse Effects Related to OTC Pain Medications

According to the American Gastroenterological Association, more than half of the stomach bleeding cases and ulcers are associated with NSAIDs. The long-term usage of NSAIDs is also likely to lead to heart and stroke risks, kidney failure and/or high blood pressure. An overdose of acetaminophen can lead to liver failure and possibly death. A heavy dosage of acetaminophen can also lead to kidney disease, GI bleeding, stroke or heart attack, and/or high blood pressure. Taking drugs for an extended time period, higher consumption of drugs than the recommended dosage, taking drugs in combination with other pain medications, and/or combining NSAIDs with alcohol increases the risk of stomach and intestinal bleeding, other adverse effects, and serious complications. Majority of patients taking over-the-counter pain medication are more concerned about reducing pain and are unaware of the adverse effects. Popular pain-relieving medicines, such as Paracetamol, Aspirin, Ibuprofen, etc., are easily available, and do not require a prescription from physicians. However, they are very effective for reducing pain only if taken as directed.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-8947

Competitive Landscape in the Global Over-the-Counter Pain Medication Market

The competition section of the over-the-counter pain medication market provides detailed information about key players competing in the over-the-counter pain medication market based on their market shares, different market strategies, product offerings, marketing approach, and company dashboard. Some of the key players featured in this over-the-counter pain medication market report are Pfizer, Inc., Johnson & Johnson Services, Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline plc., Bristol-Myers Squibb and Company, Teva Pharmaceutical Industries Ltd, Mylan N.V., Merck & Co., Cardinal Health Inc., and others.    

[fmihealthcare-blog]

Oral Antiseptics Market to Display Growth at a CAGR of 4.6% in 2028

Value–based Oral Antiseptics Products Gaining Higher Acceptance

Value based oral antiseptics products are receiving more acceptance among consumers in emerging and economically poor countries due to their cost cutbacks and associated health benefits.  In fact the outlook for entire oral care industry has changed over last 15 years, and the matter of change has affected preventive supplies like oral antiseptics as well. With rise in disposable income observed in population reaching urban lifestyle, the oral antiseptics market would observe a clinical change in current trends. Value based products are receiving more acceptance among consumers in emerging and economically poor countries due to their cost cutbacks and associated health benefits. A large portion of consumer base is directed to use oral antiseptics, due to the rise in poor dental condition present.

Distributors and Their Efficient Role in Encouraging the Market

Distributors are often looked as middle man in any industry that requires the product to be shipped to a selective class of consumers. They influence the market to have sustainable growth through its reach towards the end user. Oral antiseptics is a dental consumable which is required for dental prevention and manufactures working in this oral antiseptics industry is dependent on distributors to advance their products to the consumers as direct sales is highly present. Distributors definitely take a share in the market value chain for oral antiseptics with its attested service claims, but generates a loyal company-consumer relationship and tangible benefits. Distributors also provide market intelligence to consumers with change in trends and price adjustments required for oral antiseptics.

In this industry for oral antiseptics, the products are more driven towards the consumers by the distributors. As the market involves both OTC and prescription based products, it requires assistive market intelligence within a long chain of working bodies. Small scale oral antiseptics producers who lack supply routes and storing space tend to lose product reach, distributors play an important role in assisting such companies offering by narrow space of revenue generation.

Request Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-8871

All such factors and examples play an important role in oral antiseptics market revenue over the period and leave a clear efficient role of distributors in the oral antiseptics market.

Limited Competition Offers Attractive Room for Growth

It is still a moving opportunity for dental care manufacturers involved in oral antiseptics market. Observed discomfort and consequences with strong oral antiseptics which includes alcohol, chlorhexidine, chlorine dioxide and more tends to support and helps in the growth of herbal oral antiseptics solutions. The market for such alternative is projected to expand over the period, with equal results and less no. of physical discomfort reported in such alternatives. The market for herbal oral antiseptics is still less competitive than most other market in oral antiseptics. There are very few players actively participating in this segment of oral antiseptics.

Companies like The Natural Dentist comes up with herbal solutions, their anti-gingivitis solutions contain 20% aloe vera extract which works as an antiseptic solution and could be used as a replacement for strong compound based oral antiseptics. Aesop Mouthwash, georganics coconut oil pulling mouthwash, auromere ayurvedic mouthwash are few examples of such herbal oral antiseptics used as a dental prevention substitute for strong compound based oral antiseptics.

This opportunity lies with all of the major oral antiseptics manufacturers and also new market players planning to enter the market with new set of product offerings. Diverse product range would help in attracting more certain consumer base and result in the overall expansion of the oral antiseptics market.

Competitive Landscape

The report consists a proper assessment of companies operating in the oral antiseptics market. This section provides a detailed understanding of most competitors in the oral antiseptics market. Companies like Revive Personal Products Company, Procter & Gamble, 3M, Dentsply Sirona, Colgate-Palmolive, Johnson & Johnson, Dentaid SL, ICPA Health Products Ltd, Cipla Inc. and Church & Dwight Co., Inc. are profiled in this report. The oral antiseptics report provides latest information and key dynamics involved in the market. Current market structure and leaders of this growing market with all all-encompassing data on each oral antiseptics manufacturers is present in this report. An inclusive analyst opinion and commentary is present for each participant with brief insights in this oral antiseptics market.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-8871

About the Report: The report on oral antiseptics published by the company includes detailed insight related to the industry. The report provides a comprehensive information about the structure of this concerned market with knowledge and key inclusions required to be a part of this industry and about the most important market characteristics involved in this market, involving both demand and supply trends for the oral antiseptics market.

Segmentation: The oral antiseptics market is segmented by geographical region, product type, and distribution channel. Based on geographical region, the oral antiseptics market is segmented into seven regions – North America, Europe, Latin America, South Asia, East Asia, Oceania and the Middle East & Africa (MEA). By product type, the market is segmented Cetylpyridinium Chloride based, Chlorhexidine Gluconate based, Herbal and Essential Oils. By distribution channel, the oral antiseptics market is segmented into Retail Pharmacy, Supermarket/Hypermarket, E-commerce and Drug Stores.

Additional Questions Answered: Additionally, the report also answers rather important question from this market which contains valuable information, critical questions such as: Which product type is the latest and is estimated to grow with parallel health benefits, What should be the strategies for manufacturers in order to sustain themselves in this competitive oral antiseptics market?

Get full Report Now@ https://www.futuremarketinsights.com/checkout/8871

Research Methodology: The process of market research involves extensive secondary research of the concerned oral antiseptics market. Analysts try obtain industry-validated historic and current data about the demand for oral antiseptics across the globe. Comprehensive secondary research with assisted primary research is carried, the detailed oral antiseptics market value (US$ Million) is obtained. There are different steps in order to counter validate the final numbers, qualitative data and market understanding is converted into quantity giving out a prime market value for the industry.

[fmihealthcare-blog]

Vein Finder Market is expected to expand at 10.7% CAGR in 2028

                 Leading Manufacturers Contribute 56% of the Revenue in the Vein Finder Market

The vein finder market is largely dominated by few major manufacturers who are competing on the basis of advancement and pricing in the vein finder market. The fragmented nature of the vein finder market decreases the profitability of the business. However, the introduction of the novel device by manufacturers and the growing patient and healthcare professional satisfaction with the use of vein finder, are factors expected to boost the growth of the vein finder market. Companies such as Accuvein, Christie Medical Holdings, and OSANG Healthcare Co., Ltd. hold 56% of the revenue share in the global vein finder market.

Excellence in Customer Satisfaction and Increasing Adoption of Vein Finder

Hospitals have achieved higher customer satisfaction after using a vein finder in their facility for IV insertion and to draw blood. Vein finders help physicians and nurses to locate and access the vein easily and provide valuable information for the vascular access procedure. A vein finder increases the chances of drawing blood and inserting IV in the first attempt. This has reduced the use of multiple needles to draw blood and subsequently the pain and discomfort caused during IV insertion and blood drawing. This has, in turn, helped hospitals gain customer satisfaction and acts as the driving factor for the growth of the vein finder market.

Request Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-7640

Expansion in End Users and Applications of Vein Finder

Vein finders are very useful in hospitals, ambulatory surgical centers, clinics, diagnostic labs, and home care settings. Additionally, a vein finder is also useful at veterinary clinics. The device is not only used for spotting veins in humans, but also in animals as well. A vein finder allows simple needle insertion in the veterinary setting, reducing the challenges faced during such operations and therefore allowing more comfort to the animal. Vein finders are easy to use and save valuable time for both nurses and patients. The end-user expansion is boosting the market growth of vein finders.

Emerging Field of Mobile Health and Technology in Nursing Education

In future, Mobile health (mHealth) has huge potential to restructure healthcare delivery. Technological advances in smartphone hardware and software have shown exponential growth in the market. Mobile health is expected to play an important role in patient self-care as smartphone ownership is rising globally. It is estimated that more than 259,000 mHealth apps were accessible on app stores and accounted for approximately 3.2 billion downloads in 2017. Nowadays, innovative mobile apps that use sophisticated software to scan the skin of the patients have entered the market. User-friendly image platforms provide vein lining images to the physicians and nurses. These vein illumination mobile apps can be used by nursing practices and educational institutes.

Increased Opportunities in the Cosmetic Industry

Over the past years, the number of cosmetic surgeries among the aging population has increased. Procedures like tightening of the skin, facelift, facial & body contouring, eyelid lift, brow lift, etc. are very popular. Based on the data by the International Society of Aesthetic Plastic Surgery, cosmetic procedures and cosmetic surgery injectable increased by around 8% and 11%, respectively, in 2016. This rise in the no. of procedures increases the need for vein finder devices. However, the venipuncture technique is fairly common for cosmetic surgeries. There is a need for vein finder devices to improve their efficiency and reduce the probability of error. Vein finders help to locate facial veins to avoid bruising while performing procedures such as facial injectable.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-7640

Competitive Landscape of the Global Vein Finder Market

The competition section of the vein finder market features the profiles of the key players competing in the vein finder market based on their differential market strategies, market shares, product offerings, marketing approach, and company dashboard. Some of the key players featured in this report include AccuVein Inc., Christie Medical Holdings, Koninklijke Philips N.V, Osang Healthcare Co. Ltd, Teleflex Inc. (Acq. VueTek Scientific, LLC.), TransLite, LLC, ZD Medical, Vivolight, Venoscope LLC, and Shenzhen Bestman Instruments Co., Ltd.

The key manufacturers offer advanced vein finders. AV400 vein illuminator by AccuVein Inc. allows healthcare professionals to map veins on the patient’s skin by improving vascular access procedures such as IV insertion, blood drawing for testing and blood donation and avoiding veins for patients undergoing cosmetic injectable procedures.

[fmihealthcare-blog]

Aromatherapy Market Value is expected to US$ 8,058.5 Million by end of 2026

                            A recent study of Future Market Insights (FMI) envisages the aromatherapy market to record a healthy 7.7% value CAGR and reach US$ 8,058.5 million valuation between the period of forecast 2016 and 2026. The market is expected to experience promising growth in the near future, mainly due to the increasing health and wellness trend, and popularity of the direct sales channel. Medical centers offering therapeutic treatments have initiated promotions for the use of aromatherapy in the treatment of generic ailments such as headaches, anxiety and depression. Increasing preference for aromatherapy will also be instrumented by its efficiency in boosting cognitive performance, increasing blood circulation, strengthening immunity, improving digestion and reducing pain.

The regions of North America and Western Europe are projected to continue their dominance in the aromatherapy market. Collective revenues from aromatherapy product sales in these two regions will surpass US$ 4 billion, according to the study. However, Asia Pacific excluding Japan (APEJ) will record fastest growth in the aromatherapy market, as spa tourism is on the go in ASEAN markets, and an increasing number of women in this region are inclined to buy essential oils for home usage.

A Sample Of This Report Is Available Upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1080

Diffusers and other equipment used for extracting the aroma of plant extracts will continue to witness a slower sales growth rate as compared to consumables. Revenues from aromatherapy consumables, such as blended oils, carrier oils, will account for bulk shares of the market during the forecast period. There has been increasing usage of aromatherapy diffusers at home to ward off bad smells. The therapeutic properties of essential oils such as immune system, combating cold, allergies and breathing disorders are promoting sound sleep and relaxation at home. As a result, increasing number of people are opting to buy aromatherapy diffusers and essential oils for home usage.

Aromatherapy acts as a complementary treatment in many viral and bacterial diseases such as acute respiratory infections, viral infections, influenza, and bronchitis, and can be used during prophylactic and therapeutic treatment regime for many diseases. Owing to these added benefits and application of essential oils in many indications leads to increasing sales of essential oils for different condition which in turn drive the revenue growth of aromatherapy market.

Increasing consumer preference for aromatherapy can be attributed to its greater skin rejuvenation and hair fall control offered. This has further driven adoption of aromatherapy in skin care and hair care applications, with revenues projected to register an impressive growth through 2026. Demand for aromatherapy is also expected to rise in the treatment of insomnia, pain management, and scar management. Carrot seed, cedar wood, geranium, hyssop, juniper, rose and lavender essential oils are commonly used for scar management.

Aromatherapy market is fragmented with the presence of few established brands and many local players in the market, and the market is witnessing entry of many home-based and startup firms. The major share of market is captured by the brands such as Young Living Essential Oils, doTERRA, Now foods and Eden Garden.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-1080

Considering the growth prospects in emerging markets, various established companies and startup firms have entered aromatherapy market to capture maximum share in emerging markets, as the market is at its nascent stage where herbal products are in high demand. Companies such as Mountain Rose Herbs, Eden Garden, Frontier Natural Products Co-op (Aura Cacia) and Plant Therapy Essential Oils based in the U.S. are recognized all over the world for offering organic herbs, aromatherapy products, essential oils, and other natural health and body care products through online big retail chains and through their own website.

[fmihealthcare-blog]

Saudi Arabia Pharmaceutical Market Analysis and Forecasted Healthcare Industry With Top Industry With Key Companies by 2026

The significant rise in lifestyle-related diseases and the developments in healthcare infrastructure are expected to influence the demand for pharmaceuticals in Saudi Arabia. In 2016, the Saudi Arabia pharmaceutical market is anticipated to procure value worth US$ 5,209.5 Mn at a y-o-y growth of 6.0 % over 2015. The mounting demand for branded drug products will continue to incite the growth of the Saudi Arabian pharmaceutical market in 2016.

The demand for pharmaceuticals in Saudi Arabia is expected to register substantial growth owing to the increasing penetration of health insurance companies and the rising incidence rate of non-communicable diseases. Furthermore, the exceptional rise in the per capita income of Saudi Arabia is also expected to foster the demand for branded pharmaceutical drugs. Another key factor driving the growth of the pharmaceutical market in Saudi Arabia is the country’s strategic move to allow 100% FDI in the pharmaceuticals sector. Although, the shortage of profound indigenous research capacity in the pharmaceutical industry and the delayed registration of drug and medicine patents is expected to limit the expansion of the market in 2016 and beyond.

Based on the product type, the pharmaceutical market in Saudi Arabia is expected to witness an upsurge in the prescription-type branded drug products. In terms of market value, the branded drugs are estimated to reach US$ 2,760.8 Mn by 2016-end. The demand for generic drugs is projected to secure steady growth, attributing to the insisting promotion of generic drug adoption by healthcare insurance providers.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gc-1733

On the basis of the diseases, the pharmaceutical drugs used for treatment of cardiovascular diseases will continue exhibiting robust growth in 2016. The demand for cardiovascular medications will continue to surge due to the prominence of circulatory disorders in Saudi Arabia. Additionally, the rising prevalence of disorders related to body sugar levels is expected to make diabetes a rapidly growing disease-based sub-segment in the Saudi Arabia pharmaceutical market.

The pharmaceutical market in Saudi Arabia is also segmented on the basis of distribution channel, where retail pharmacies will continue to account for 80% market share compared to hospital pharmacies. The westernised modernisation of retail pharmacies in Saudi Arabia has led to the availability of a wide range drugs and medicinal products, thereby attaining a considerable growth in the retail pharmacy sub-segment in 2016 and further.

The rising resource potential in Saudi Arabia is projected to positively reform the production environment for pharmaceutical manufacturers. In order to expand the market’s size, structuring alliances with well-established native companies is predicted to be a key strategy for global pharmaceutical leaders. The key players in the Saudi Arabia pharmaceutical market include Novartis AG, SPIMACO, Pfizer Inc., and Glaxosmithkline plc., Jamjoom Pharma,  and Tabuk Pharmaceutical Manufacturing Co. among others.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gc-1733

Long-term Outlook: The Saudi Arabia pharmaceutical market is expected to expand at a CAGR of 9.0% over the forecast period 2016-2026. In terms of market value, the pharmaceutical market in Saudi Arabia is estimated to be worth US$ 12,281.4 Mn by the end of forecast period.

[fmihealthcare-blog]

Platelet Rich Plasma (PRP) Market: Global Industry Analysis and Opportunity and Forecast by 2026

The global platelet rich plasma (PRP) market is projected to witness a year-over-year growth rate of 11.8% in 2016 over 2015 to reach US$ 224.0 Mn in revenues. Increase in the number of patients suffering from orthopaedic injuries and widening application area of PRP in different surgeries is likely to catalyse the market the growth. Use of PRP therapy in treating sports injuries is also anticipated to boost the growth of the market.

By type, pure PRP is likely to dominate product segment in 2016 with the revenue share of about 65%. The segment is also forecast to dominate other application segments through the forecast period. This segment is estimated to witness a year-over-year growth of 11.4% to reach US$ 144.3 Mn in revenues in 2016. Pure PRF/Leukocyte rich PRF segment is projected to register impressive year-over-year growth of 15.5% in 2016.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1722  

By origin, autologous segment will continue to be the prominent segment in 2016, accounting for three fourth of total revenue generated in the year. This segment will witness a year-over-year growth of 11.0% to reach US$ 169.1 Mn in revenues in 2016. Autologous segment among other PRP origins is slated to reflect moderate market performance in 2016, is likely to lose market share to allogenic PRP over next four to five years. Allogenic segment is also projected to register an impressive year-over-year growth of nearly 15% in 2016.

Examining the PRP demand statistics from different surgeries clearly forebodes the dominance of orthopaedic surgery. Currently, orthopaedic surgery is the leading application segment accounting for a revenue share of over 35% in 2016.Orthopaedic surgery is followed by cosmetic surgery, which is estimated to be valued over US$ 50 Mn in 2016. Cosmetic surgery will continue to remain the second-largest application segment, with total revenues expected to reach US$ 59.6 Mn by 2016 end.

In terms of geography, North America, being the advanced market, characterized by early adopters of PRP based therapies. The market in North America is estimated to increase by 11.4% in 2016 to reach very close to US$ 120 Mn. Growth of the market in this region is supported by increasing number of cosmetic and orthopaedic surgeries. Moreover, the region is home to some of the most prominent players operating in the PRP market and hence awareness among patients is also high. Awareness among healthcare community as well as patients is also anticipated to fuel the growth of in North American market.

Adoption of PRP therapy in Asia Pacific is growing at a brisk pace, fuelled by the region’s status as an epicentre of medical tourism. The region has a high geriatric population, and adoption of PRP therapy has witnessed a surge in the recent past. The APAC plasma therapy market is anticipated to increase at a year-on-year growth rate of 16.1% in 2016 to reach US$ 40.5 Mn in revenues.

Request to View Methodology @  https://www.futuremarketinsights.com/askus/rep-gb-1722

Key players operating in the global platelet rich plasma market are Harvest Technologies Corp., Biomet, Inc., Arthrex, Inc. and Arteriocyte Medical Systems, Inc. Dr. PRP America, Cesca Therapeutics, Inc., and Regen Lab SA.

Long-term Outlook: The global platelet rich plasma market is projected to increase at a CAGR of over 12.0% during the forecast period from 2016-2026. North America is forecast to dominate the global market throughout the forecast period, whereas orthopaedic surgery will be the largest application segment

[fmihealthcare-blog]

Traditional Wound Management Market Detailed Report With Growth Opportunity & Forecast - 2026

Wound care management is a billion-dollar market accounting for a massive proportion of the healthcare expenses worldwide. Inter- and intra-departmental collaborations between surgeons and their support staff, i.e. the nurses, plays a key role in better wound management. This also determines the usage pattern for traditional wound management products, order placement cycles and choosing preferred vendors. The application of customer analytics and critical vendor management strategies are factors that are likely to fuel the demand for traditional wound management products, according to the Future Market Insights report on the global traditional wound management market. According to this report, the global traditional wound management market is estimated to expand by 1.4x in terms of value over 2016–2026, to reach a value of US$ 1,792 Mn by the end of 2026.

The gauzes product type segment contributed the highest revenue share in the global traditional wound management market in 2016. The usage of cotton gauze traditional wound management products for medical dressings, bandages, production of wound adhesions and many others is facilitating the growth of this segment in global traditional wound management market. Its non-adherent nature makes it more popular over other traditional wound management products.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-857

Increase in outpatient wound care practices in ambulatory care centers is fuelling the usage of traditional wound management products. Moreover, traditional wound management products are witnessing demand from outpatient centers owing to low cost and easy availability as compared to advanced wound care products. Ambulatory care practices are also increasing due to the preference for minimally invasive or outpatient-based surgeries in the U.S and Europe. The development and incorporation of wound-care curriculum is boosting the usage of traditional wound management products among end users. Discussions with suppliers in the market revealed that the development and incorporation of wound-care curriculum in larger hospitals has improved product consumption/usage. This happens through continued education and rising awareness among caregivers regarding the proper usage of products, thus facilitating effective wound care consistent with the current “best practices.” These factors eventually help ensure best patient experiences as well as develop brand loyalty for traditional wound management products.

The improvement and streamlining of regulatory processes in developing countries is expected to boost the formalisation of practice standards, the development of better clinical treatment guidelines, the standardisation of product usage, and the strengthening of the registration & licensing period required for traditional wound management products. This is expected to help companies operating in the traditional wound management market ensure that their products comply with the quality, safety and hygiene norms designed by nodal regulatory bodies such the U.S. CDC, Australian TGA and U.K. NHS, among others.

Among all regions, North America dominated the global market for traditional wound management and is expected to continue to maintain its dominance. In spite of the availability of more convenient and advanced wound healing products, majority of healthcare professionals opt for the usage of traditional wound management products due to cost-effectiveness and the availability of clear reimbursement policies for these products in countries such as the U.S. The APEJ traditional wound management market is estimated to expand at the highest CAGR over 2016–2026. Decreasing prices of cotton as a raw material for traditional wound management products in countries such as India and China is contributing to the high growth of the APEJ traditional wound management market.

Request to View Methodology @ https://www.futuremarketinsights.com/askus/rep-gb-857

Although traditional wound management constitutes the largest revenue share for total wound management, it is low-margin in nature. Most of the raw materials such as cotton, are exported from developing markets to markets that have a strong manufacturing base and high sales of finished products. Trading of these raw materials in traditional wound management market takes place at subsistence levels as these markets are mostly unorganized in nature. Lack of attractive margins is discouraging retailers from the business of traditional wound management products, and their focus is gradually shifting to the business of advanced wound care management products.

The global traditional wound management market is highly fragmented with a large number of regional and local players operating in the global market. Reimbursement service providers are more focused on providing reliable and cost-effective wound management solution to patients.